5th LNP Formulation and Process Development Summit

LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly and Co/Verve Therapeutics and Bristol Myers Squibb/Orbital Therapeutics. Validating LNPs as a stand-out delivery vehicle for cell and gene therapies!

Returning to Boston in April 2026, the 5th LNP Formulation and Process Development Summit is an industry-led end-to-end meeting providing the latest scientific content to advance LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. This is your one-stop shop to hear insights on LNP discovery, analytics, formulation, process development and large-scale manufacturing.

With 3 focused streams, Analytical Development and Characterization, Formulation and Delivery and Process Development and Manufacturing, this is your opportunity to overcome challenges in achieving precise extrahepatic delivery, robust characterization of targeted LNPs and optimal formulations for ambient storage, all towards making LNP drug products more selective, safe and potent.

Uniting 250+ global LNP trailblazers, gain exclusive access to LNP specific networking, partnership opportunities and collaborative discussions to drive the next-generation of LNPs towards the clinic.


URLs:
Website: https://go.evvnt.com/3347173-0?pid=2874
Brochure: https://go.evvnt.com/3347173-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Prices:
Drug Developer Pricing (Conference + Pre-Conference Day): USD 4197.00,
Drug Developer Pricing (Conference Only): USD 2999.00,
Academic Pricing (Conference + Pre-Conference Day): USD 3597.00,
Academic Pricing (Conference Only): USD 2599.00,
Service Provider Pricing (Conference + Pre-Conference Day): USD 5197.00,
Service Provider Pricing (Conference Only): USD 3799.00

Speakers: Emma Wang, Chief Technology Officer, YolTech Therapeutics, Rajul Jain, Managing Director, Vida Ventures, Anni Chang, Senior Scientist II, USP, Evan Williams, Professor University of California, Berkeley, Isabelle Gusev, Principal Scientist and Group Leader, Analytical Development, CMC, Tessera Therapeutics, Matthew Reynolds-Tejeda, Senior Associate Scientist, Nanoparticle Process Development, Strand Therapeutics, Lokesh Narsineni, Senior Scientist, Process Sciences, Scribe Therapeutics, Dan Shores, Partner, Rothwell Figg, Douglas Scott, Scientist II, LNP Formulations and Process Development, Prime Medicine, Jennifer Zachry, Co-Founder, Director, Business Development, Orion Therapeutics, Padma Malyala, Chief Technology Officer, nChroma Bio, Amit Singh, Director, Delivery Discovery, Mote Therapeutics, Michael Smith, Director, Emerging Technologies, Moderna, Roger Adami, Chief Technology Officer, Land Therapeutics, Zach Zhu, Chief Technology Officer, Innorna, Issi Rozen, General Partner, Google Ventures, Mercedes Segura Gally, Vice President, Process Development, Editas Medicine, Urmi Chheda, Senior Process Engineer, Editas Medicine, Andrzej Pitek, Delivery Expert, Andrew Cornforth, Chief Technology Officer, Corner Therapeutics, Adrian Bot, Scientific, Executive Officer, Vice President - Research Development, Capstan Therapeutics, Arnab Rudra, Visiting Scientist, Boston Children's Hospital, Morgan Urello, Principal Scientist, Nucleic Acid Delivery, Biotech Startup, Delai Chen, Director, Nanoparticle Formulation, Beam Therapeutics, Ronen Eavri, Chief Executive Officer and Co-Founder, Barcode Nanotech, Kinkini Roy, PhD Associate Director - Drug Product Development, Aviceda Therapeutics, Brenda Star Clemente, Director, Drug Product Process Development, Arcturus Therapeutics, Shengshuang Zhu, Senior Principal Scientist, Arbor Biotech, Jamie Tsung, Director, Drug Product Formulation, CMC Development, Alnylam, Harsh Chauhan, Director, Formulation Development and External Manufacturing, Alltrna, Daryl Drummond, Chief Scientific Officer, Akagera Medicines, Bo Ying, Chief Executive Officer, Abogen Biosciences, Raquib Hasan, Senior Scientist, Advanced Technologies, Drug Product Development, Takeda, Geoffrey Prevot, Scientist, Early Formulation and Drug Profiling, Servier, Saikat Manna, Senior Scientist, Delivery and Formulation, Sanofi, Natalya Martin, Principal Scientist, Sanofi, Saswata Karmakar, Director, Platform Chemistry, Sanofi, Eric Holowka, Associate Director, Drug Delivery Innovation, Regeneron, Aishwarya Saraswat, Senior Scientist, Formulation Development Group, Regeneron, Shruti Trivedi, Scientist, Pfizer, Matt Eastwood, Scientist II, Nucleic Acid Delivery, Novo Nordisk, Hongjing Xia, Principal Scientist II, Novartis, James Deng, Associate Principal Scientist, Vaccine Analytical Research and Development, Merck and Co, Bader Jarai, Principal Scientist, Drug Product Development and Delivery, Johnson and Johnson, Rushit Lodaya, Associate Director, RNA Delivery Sciences, GlaxoSmithKline, Daniel Estabrook, Senior Advisor, Bioproduct Research and Development, Eli Lilly and Co., Ester Caffarel-Salvador, Director, Strategic Innovation, Chiesi Global Rare Diseases, Liping Zhou, Senior Director, Advanced Drug Delivery, AstraZeneca, Ching Kim Tye, Head of Lipid Nanoparticle and Platform Development, Sanofi, Luis Brito, Vice President, Delivery Platform, Beam Therapeutics, Annette Bak, Head of Advanced Drug Delivery, AstraZeneca